SM
BLRX

Sabby Management’s BioLineRX BLRX Stock Holding History

Sabby Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-69
Closed -$504K – 65
2023
Q3 		$504K Buy
69
+42
+156% +$2.82K 0.37% 16
2023
Q2 		$174K Buy
+27
New +$1.5K 0.14% 53

Other funds holding BLRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management's BLRX Position: Q4 2023 in Review

Sabby Management sold out of BioLineRX (BLRX) in Q4 2023, closing a stake of 5,250 shares — an estimated $382K sold.

Sabby Management first reported a position in BLRX in Q1 2014 and held it in 10 quarters. The position peaked at $4.24M in Q1 2014. 29 funds tracked by Wall St. Rank hold BLRX as of Q4 2023.

  • Sabby Management reported no remaining BioLineRX position as of Q4 2023 after selling out during the quarter.
  • Sabby Management sold 5,250 BioLineRX shares in Q4 2023, an estimated $382K.
  • Sabby Management first reported a position in BioLineRX in Q1 2014 and held it in 10 quarters.
  • Sabby Management's BioLineRX position peaked at $4.24M in Q1 2014.
  • 29 funds tracked by Wall St. Rank held BioLineRX as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.